What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks to buy now. Piper Sandler revised the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $84 from $122 on February 6 and maintained an Overweight rating on the shares.

In another development, Barclays assumed coverage of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with an Overweight rating and an $80 price target on January 27. The firm initiated coverage of 12 biotech stocks, assuming coverage of 11 with an optimistic outlook for the industry. Barclays stated that it likes the setup for the group in 2026, and anticipates “significant tailwinds” in the year, such as continued mergers and acquisitions, a reduced focus on drug pricing, and “strong” underlying fundamentals.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) also received a rating update from Canaccord Genuity on January 20, with the firm upgrading it to Buy from Hold and adjusting the price target from $98 to $84. Canaccord believes the pending acquisition of Amicus to be the key catalyst that breaks BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) shares out of the recent trading range, expecting that positive pipeline and commercial updates “could more meaningfully and durably shift sentiment” once the deal closes. This may help close the company’s “valuation gap”, according to the firm.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307. It pursues bold science to translate genetic discoveries into new medicines, advancing the future of human health.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.